Cell and Biologic-Based Treatment of Flexor Tendon Injuries

详细信息    查看全文

• 作者：Stephen W. Linderman ; MPhil^⁎ ; ^&dagger ; ; Richard H. Gelberman ; MD^⁎ ; Stavros Thomopoulos ; PhD^&Dagger ; ; ^§ ; ; Hua Shen ; MD ; PhD^⁎ ; ^{shenhu@wudosis.wustl.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：flexor tendon repair ; cell ; growth factor ; tissue engineering
• 刊名：Operative Techniques in Orthopaedics
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：26
• 期：3
• 页码：206-215
• 全文大小：8145 K

文摘

The 2 primary factors leading to poor clinical results after intrasynovial tendon repair are adhesion formation within the digital sheath and repair-site elongation and rupture. As the outcomes following modern tendon multistrand repair and controlled rehabilitation techniques are often unsatisfactory, alternative approaches, such as the application of growth factors and mesenchymal stem cells, have become increasingly attractive treatment options. Successful biological therapies require carefully controlled spatiotemporal delivery of cells, growth factors, and biocompatible scaffold matrices to simultaneously (1) promote matrix synthesis at the tendon repair site leading to increased biomechanical strength and stiffness and (2) suppress matrix synthesis along the tendon surface and synovial sheath preventing adhesion formation. This article summarizes recent cell and biologic-based experimental treatments for flexor tendon injury, with an emphasis on large animal translational studies.